On October 27, 2026, the Food and Drug Administration issued draft guidance creating an approval framework for individualized gene editing therapies targeting rare disease mutations. The policy allows drugmakers to clear subsequent mutation treatments using lab data after initial trial approval. Following the announcement, shares of Prime Medicine rose 15% and Beam Therapeutics rose 8%. Concurrently, the Centers for Medicare and Medicaid Services plans to expand Medicaid access to gene therapies.
FDA draft guidance on gene editing
- ▪Under the proposed Food and Drug Administration guidance, a drugmaker could win initial approval for a gene therapy using traditional clinical trials and later obtain clearance for different mutations using laboratory data
- ▪The Food and Drug Administration, in its October 27, 2026 draft guidance, proposed defining parameters for future mutation clearances within an 'individualized feature space' in a drugmaker's original therapy application
- ▪The FDA issued draft guidance establishing a regulatory framework for personalized gene editing therapies targeting different mutations in the same disease-causing gene
Economic viability of rare disease drugs
- ▪Developing individual treatments requiring full clinical studies is often not profitable for drugmakers because many rare disease mutations affect extremely small patient populations
- ▪TD Cowen analyst Joseph Thome noted that the Food and Drug Administration's October 27, 2026 draft guidance provides 'plug and play' optionality that could improve the economic viability of rare disease drug development
FDA rare disease events and outreach
- ▪Food and Drug Administration officials attended a rare disease summit in Washington during the week of October 28, 2026, as part of broader agency outreach
- ▪The Food and Drug Administration scheduled a meeting on October 28, 2026, at its White Oak campus to discuss its 'Rare Disease Framework Initiative.'
CMS expansion of Medicaid therapy access
- ▪Beam Therapeutics Chief Executive Officer John Evans publicly characterized the Centers for Medicare and Medicaid Services plan to broaden Medicaid therapy access as 'great news.'
- ▪The Centers for Medicare and Medicaid Services is looking to broaden a program providing Medicaid patients access to cell and gene therapies beyond its initial focus on sickle cell disease
Story comments
Loading comments…